GlassScriptPhysician profile
Apexa H Trivedi
NPI 1114632775
$2,538.36
in general payments reported to CMS, 2019-2025
24 companies · $1,306 in 2025
The $1,306 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $299 · 2024: $934 · 2025: $1,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,508 · Long Term Medical Supply Or Device Loan: $29.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,508.39 |
| Long Term Medical Supply Or Device Loan | $29.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $442.70 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $412.37 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $207.96 | 2024-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Xeris Pharmaceuticals, INC. | $202.89 | 2024-2025 | Gvoke Hypopen |
| Pfizer INC. | $182.87 | 2023-2025 | |
| Amgen INC. | $161.59 | 2023-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $147.07 | 2023-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $143.23 | 2023-2024 | Xarelto |
| Astellas Pharma US INC | $127.43 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $81.83 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $70.37 | 2023-2025 | |
| Boston Scientific Corporation | $69.31 | 2025 | Bodyguardian |
| Phathom Pharmaceuticals, INC. | $40.02 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $35.08 | 2025 | Shingrix, Arexvy |
| Axsome Therapeutics, INC. | $34.89 | 2025 | Auvelity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $33.67 | 2024 | Azstarys |
| Shield Therapeutics INC | $29.75 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.71 | 2025 | Xifaxan |
| Collegium Pharmaceutical, INC. | $17.83 | 2025 | Jornay Pm |
| Becton, Dickinson and Company | $17.34 | 2024 | Bd Onclarity |
| Novartis Pharmaceuticals Corporation | $17.06 | 2024 | |
| Edwards Lifesciences Corporation | $15.55 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Merck Sharp & Dohme LLC | $14.70 | 2024 | Gardasil, Gardasil 9, M-M-R II |
| E.R. Squibb & Sons, L.L.C. | $13.14 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Apexa Trivedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.